• Company
• 2nd generation EGFR TKI Vizimpro can be prescribed in Big 5
• by Eo, Yun-Ho Jul 6, 2022 05:47am

• Company
• There are many complaints about the revaluation of generics
• by Chon, Seung-Hyun Jul 6, 2022 05:46am

• Policy
• Antiepileptic perampanel’s adverse event rate at 32%
• by Lee, Hye-Kyung Jul 5, 2022 05:59am

• Policy
• The revaluation of Streptokinase could be maintained for 1yr
• by Lee, Tak-Sun Jul 5, 2022 05:59am

• Company
• Sanofi & MDsquare co-promote Digital Healthcare Business
• by Jul 5, 2022 05:58am

• Company
• RDK introduces monkeypox PCR test kits to Korea
• by Jul 5, 2022 05:58am

• Policy
• Support for online conferences will be extended for 1 yr
• by Kim, Jung-Ju Jul 5, 2022 05:58am

• InterView
• "Leclaza’s mOS data of 38.9 months is remarkable"
• by Kim, Jin-Gu Jul 4, 2022 05:55am

• Opinion
• [Reporter's view] Looking forward to another K-COVID vaccine
• by Lee, Hye-Kyung Jul 4, 2022 05:55am

• Company
• CKD voluntarily discontinues P3T on its COVID-19 therapy
• by Kim, Jin-Gu Jul 4, 2022 05:55am